Skip to main content
Top
Published in: Journal of Translational Medicine 1/2010

Open Access 01-12-2010 | Research

Thymoglobulin, interferon-γ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures

Authors: Giuseppina Bonanno, Paola Iudicone, Andrea Mariotti, Annabella Procoli, Annino Pandolfi, Daniela Fioravanti, Maria Corallo, Alessandro Perillo, Giovanni Scambia, Luca Pierelli, Sergio Rutella

Published in: Journal of Translational Medicine | Issue 1/2010

Login to get access

Abstract

Background

Cytokine-induced killer (CIK) cells are typically differentiated in vitro with interferon (IFN)-γ and αCD3 monoclonal antibodies (mAb), followed by the repeated provision of interleukin (IL)-2. It is presently unknown whether thymoglobulin (TG), a preparation of polyclonal rabbit γ immunoglobulins directed against human thymocytes, can improve the generation efficiency of CIK cells compared with αCD3 mAb in a clinical-grade culture protocol.

Methods

Peripheral blood mononuclear cells (PBMC) from 10 healthy donors and 4 patients with solid cancer were primed with IFN-γ on day 0 and low (50 ng/ml), intermediate (250 ng/ml) and high (500 ng/ml) concentrations of either αCD3 mAb or TG on day 1, and were fed with IL-2 every 3 days for 21 days. Aliquots of cells were harvested weekly to monitor the expression of representative members of the killer-like immunoglobulin receptor (KIR), NK inhibitory receptor, NK activating receptor and NK triggering receptor families. We also quantified the frequency of bona fide regulatory T cells (Treg), a T-cell subset implicated in the down-regulation of anti-tumor immunity, and tested the in vitro cytotoxic activity of CIK cells against NK-sensitive, chronic myeloid leukaemia K562 cells.

Results

CIK cells expanded more vigorously in cultures supplemented with intermediate and high concentrations of TG compared with 50 ng/ml αCD3 mAb. TG-driven CIK cells expressed a constellation of NK activating/inhibitory receptors, such as CD158a and CD158b, NKp46, NKG2D and NKG2A/CD94, released high quantities of IL-12p40 and efficiently lysed K562 target cells. Of interest, the frequency of Treg cells was lower at any time-point compared with PBMC cultures nurtured with αCD3 mAb. Cancer patient-derived CIK cells were also expanded after priming with TG, but they expressed lower levels of the NKp46 triggering receptor and NKG2D activating receptor, thus manifesting a reduced ability to lyse K562 cells.

Conclusions

TG fosters the generation of functional CIK cells with no concomitant expansion of tumor-suppressive Treg cells. The culture conditions described herein should be applicable to cancer-bearing individuals, although the differentiation of fully functional CIK cells may be hindered in patients with advanced malignancies.
Appendix
Available only for authorised users
Literature
1.
go back to reference Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA: Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982, 155: 1823-1841. 10.1084/jem.155.6.1823.PubMedCrossRef Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA: Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982, 155: 1823-1841. 10.1084/jem.155.6.1823.PubMedCrossRef
2.
go back to reference Phillips JH, Lanier LL: Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med. 1986, 164: 814-825. 10.1084/jem.164.3.814.PubMedCrossRef Phillips JH, Lanier LL: Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med. 1986, 164: 814-825. 10.1084/jem.164.3.814.PubMedCrossRef
3.
go back to reference Introna M, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, Dander E, Gaipa G, D'Amico G, Biagi E: Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica. 2007, 92: 952-959. 10.3324/haematol.11132.PubMedCrossRef Introna M, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, Dander E, Gaipa G, D'Amico G, Biagi E: Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica. 2007, 92: 952-959. 10.3324/haematol.11132.PubMedCrossRef
4.
go back to reference Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL: Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991, 174: 139-149. 10.1084/jem.174.1.139.PubMedCrossRef Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL: Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991, 174: 139-149. 10.1084/jem.174.1.139.PubMedCrossRef
5.
go back to reference Mehta BA, Schmidt-Wolf IG, Weissman IL, Negrin RS: Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+CD56+ killer cells. Blood. 1995, 86: 3493-3499.PubMed Mehta BA, Schmidt-Wolf IG, Weissman IL, Negrin RS: Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+CD56+ killer cells. Blood. 1995, 86: 3493-3499.PubMed
6.
go back to reference Verneris MR, Karami M, Baker J, Jayaswal A, Negrin RS: Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood. 2004, 103: 3065-3072. 10.1182/blood-2003-06-2125.PubMedCrossRef Verneris MR, Karami M, Baker J, Jayaswal A, Negrin RS: Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood. 2004, 103: 3065-3072. 10.1182/blood-2003-06-2125.PubMedCrossRef
7.
go back to reference Verneris MR, Ito M, Baker J, Arshi A, Negrin RS, Shizuru JA: Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma. Biol Blood Marrow Transplant. 2001, 7: 532-542. 10.1016/S1083-8791(01)70014-6.PubMedCrossRef Verneris MR, Ito M, Baker J, Arshi A, Negrin RS, Shizuru JA: Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma. Biol Blood Marrow Transplant. 2001, 7: 532-542. 10.1016/S1083-8791(01)70014-6.PubMedCrossRef
8.
go back to reference Kim HM, Lim J, Kang JS, Park SK, Lee K, Kim JY, Kim YJ, Hong JT, Kim Y, Han SB: Inhibition of human cervical carcinoma growth by cytokine-induced killer cells in nude mouse xenograft model. Int Immunopharmacol. 2009, 9: 375-380. 10.1016/j.intimp.2008.12.001.PubMedCrossRef Kim HM, Lim J, Kang JS, Park SK, Lee K, Kim JY, Kim YJ, Hong JT, Kim Y, Han SB: Inhibition of human cervical carcinoma growth by cytokine-induced killer cells in nude mouse xenograft model. Int Immunopharmacol. 2009, 9: 375-380. 10.1016/j.intimp.2008.12.001.PubMedCrossRef
9.
go back to reference Sweeney TJ, Mailander V, Tucker AA, Olomu AB, Zhang W, Cao Y, Negrin RS, Contag CH: Visualizing the kinetics of tumor-cell clearance in living animals. Proc Natl Acad Sci USA. 1999, 96: 12044-12049. 10.1073/pnas.96.21.12044.PubMedPubMedCentralCrossRef Sweeney TJ, Mailander V, Tucker AA, Olomu AB, Zhang W, Cao Y, Negrin RS, Contag CH: Visualizing the kinetics of tumor-cell clearance in living animals. Proc Natl Acad Sci USA. 1999, 96: 12044-12049. 10.1073/pnas.96.21.12044.PubMedPubMedCentralCrossRef
10.
go back to reference Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IG: Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 2010 Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IG: Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 2010
11.
go back to reference Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS: A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2005, 11: 181-187. 10.1016/j.bbmt.2004.11.019.PubMedCrossRef Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS: A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2005, 11: 181-187. 10.1016/j.bbmt.2004.11.019.PubMedCrossRef
12.
go back to reference Olioso P, Giancola R, Di Riti M, Contento A, Accorsi P, Iacone A: Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol. 2009, 27: 130-139. 10.1002/hon.886.PubMedCrossRef Olioso P, Giancola R, Di Riti M, Contento A, Accorsi P, Iacone A: Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol. 2009, 27: 130-139. 10.1002/hon.886.PubMedCrossRef
13.
go back to reference Deeks ED, Keating GM: Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection. Drugs. 2009, 69: 1483-1512. 10.2165/00003495-200969110-00007.PubMedCrossRef Deeks ED, Keating GM: Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection. Drugs. 2009, 69: 1483-1512. 10.2165/00003495-200969110-00007.PubMedCrossRef
14.
go back to reference Myint AA, Malkovska V, Morgan S, Luckit J, Wonke B, Gordon-Smith EC: Antilymphocyte globulin therapy enhances impaired function of natural killer cells and lymphokine activated killer cells in aplastic anaemia. Br J Haematol. 1990, 75: 578-584. 10.1111/j.1365-2141.1990.tb07802.x.PubMedCrossRef Myint AA, Malkovska V, Morgan S, Luckit J, Wonke B, Gordon-Smith EC: Antilymphocyte globulin therapy enhances impaired function of natural killer cells and lymphokine activated killer cells in aplastic anaemia. Br J Haematol. 1990, 75: 578-584. 10.1111/j.1365-2141.1990.tb07802.x.PubMedCrossRef
15.
go back to reference Rutella S, Pierelli L, Bonanno G, Sica S, Ameglio F, Capoluongo E, Mariotti A, Scambia G, d'Onofrio G, Leone G: Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells. Blood. 2002, 100: 2562-2571. 10.1182/blood-2001-12-0291.PubMedCrossRef Rutella S, Pierelli L, Bonanno G, Sica S, Ameglio F, Capoluongo E, Mariotti A, Scambia G, d'Onofrio G, Leone G: Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells. Blood. 2002, 100: 2562-2571. 10.1182/blood-2001-12-0291.PubMedCrossRef
16.
go back to reference Rutella S, Pierelli L, Bonanno G, Mariotti A, Sica S, Sora F, Chiusolo P, Scambia G, Rumi C, Leone G: Immune reconstitution after autologous peripheral blood progenitor cell transplantation: effect of interleukin-15 on T-cell survival and effector functions. Exp Hematol. 2001, 29: 1503-1516. 10.1016/S0301-472X(01)00747-0.PubMedCrossRef Rutella S, Pierelli L, Bonanno G, Mariotti A, Sica S, Sora F, Chiusolo P, Scambia G, Rumi C, Leone G: Immune reconstitution after autologous peripheral blood progenitor cell transplantation: effect of interleukin-15 on T-cell survival and effector functions. Exp Hematol. 2001, 29: 1503-1516. 10.1016/S0301-472X(01)00747-0.PubMedCrossRef
17.
go back to reference Rutella S, Bonanno G, Procoli A, Mariotti A, de Ritis DG, Curti A, Danese S, Pessina G, Pandolfi S, Natoni F: Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood. 2006, 108: 218-227. 10.1182/blood-2005-08-3141.PubMedCrossRef Rutella S, Bonanno G, Procoli A, Mariotti A, de Ritis DG, Curti A, Danese S, Pessina G, Pandolfi S, Natoni F: Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood. 2006, 108: 218-227. 10.1182/blood-2005-08-3141.PubMedCrossRef
18.
go back to reference Cholujova D, Jakubikova J, Kubes M, Arendacka B, Sapak M, Ihnatko R, Sedlak J: Comparative study of four fluorescent probes for evaluation of natural killer cell cytotoxicity assays. Immunobiology. 2008, 213: 629-640. 10.1016/j.imbio.2008.02.006.PubMedCrossRef Cholujova D, Jakubikova J, Kubes M, Arendacka B, Sapak M, Ihnatko R, Sedlak J: Comparative study of four fluorescent probes for evaluation of natural killer cell cytotoxicity assays. Immunobiology. 2008, 213: 629-640. 10.1016/j.imbio.2008.02.006.PubMedCrossRef
19.
go back to reference Rutella S, Bonanno G, Marone M, De Ritis D, Mariotti A, Voso MT, Scambia G, Mancuso S, Leone G, Pierelli L: Identification of a novel subpopulation of human cord blood CD34-CD133-CD7-CD45+lineage- cells capable of lymphoid/NK cell differentiation after in vitro exposure to IL-15. J Immunol. 2003, 171: 2977-2988.PubMedCrossRef Rutella S, Bonanno G, Marone M, De Ritis D, Mariotti A, Voso MT, Scambia G, Mancuso S, Leone G, Pierelli L: Identification of a novel subpopulation of human cord blood CD34-CD133-CD7-CD45+lineage- cells capable of lymphoid/NK cell differentiation after in vitro exposure to IL-15. J Immunol. 2003, 171: 2977-2988.PubMedCrossRef
20.
go back to reference Lecoeur H, de Oliveira-Pinto LM, Gougeon ML: Multiparametric flow cytometric analysis of biochemical and functional events associated with apoptosis and oncosis using the 7-aminoactinomycin D assay. J Immunol Methods. 2002, 265: 81-96. 10.1016/S0022-1759(02)00072-8.PubMedCrossRef Lecoeur H, de Oliveira-Pinto LM, Gougeon ML: Multiparametric flow cytometric analysis of biochemical and functional events associated with apoptosis and oncosis using the 7-aminoactinomycin D assay. J Immunol Methods. 2002, 265: 81-96. 10.1016/S0022-1759(02)00072-8.PubMedCrossRef
21.
go back to reference Kim GG, Donnenberg VS, Donnenberg AD, Gooding W, Whiteside TL: A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay. J Immunol Methods. 2007, 325: 51-66. 10.1016/j.jim.2007.05.013.PubMedPubMedCentralCrossRef Kim GG, Donnenberg VS, Donnenberg AD, Gooding W, Whiteside TL: A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay. J Immunol Methods. 2007, 325: 51-66. 10.1016/j.jim.2007.05.013.PubMedPubMedCentralCrossRef
22.
go back to reference Bonanno G, Procoli A, Mariotti A, Corallo M, Perillo A, Danese S, De Cristofaro R, Scambia G, Rutella S: Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignancies. J Transl Med. 2010, 8: 114-10.1186/1479-5876-8-114.PubMedPubMedCentralCrossRef Bonanno G, Procoli A, Mariotti A, Corallo M, Perillo A, Danese S, De Cristofaro R, Scambia G, Rutella S: Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignancies. J Transl Med. 2010, 8: 114-10.1186/1479-5876-8-114.PubMedPubMedCentralCrossRef
23.
go back to reference Liu Z, Fang Y, Wang X, Wang P, Yun P, Xu H: Upregulation of molecules associated with T-regulatory function by thymoglobulin pretreatment of human CD4+ cells. Transplantation. 2008, 86: 1419-1426. 10.1097/TP.0b013e318187c2e5.PubMedCrossRef Liu Z, Fang Y, Wang X, Wang P, Yun P, Xu H: Upregulation of molecules associated with T-regulatory function by thymoglobulin pretreatment of human CD4+ cells. Transplantation. 2008, 86: 1419-1426. 10.1097/TP.0b013e318187c2e5.PubMedCrossRef
24.
go back to reference Malek TR, Bayer AL: Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol. 2004, 4: 665-674. 10.1038/nri1435.PubMedCrossRef Malek TR, Bayer AL: Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol. 2004, 4: 665-674. 10.1038/nri1435.PubMedCrossRef
25.
go back to reference Ahmadzadeh M, Rosenberg SA: IL-2 administration increases CD4+CD25hiFoxp3+ regulatory T cells in cancer patients. Blood. 2006, 107: 2409-2414. 10.1182/blood-2005-06-2399.PubMedPubMedCentralCrossRef Ahmadzadeh M, Rosenberg SA: IL-2 administration increases CD4+CD25hiFoxp3+ regulatory T cells in cancer patients. Blood. 2006, 107: 2409-2414. 10.1182/blood-2005-06-2399.PubMedPubMedCentralCrossRef
26.
go back to reference Wei S, Kryczek I, Edwards RP, Zou L, Szeliga W, Banerjee M, Cost M, Cheng P, Chang A, Redman B: Interleukin-2 administration alters the CD4+FoxP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res. 2007, 67: 7487-7494. 10.1158/0008-5472.CAN-07-0565.PubMedCrossRef Wei S, Kryczek I, Edwards RP, Zou L, Szeliga W, Banerjee M, Cost M, Cheng P, Chang A, Redman B: Interleukin-2 administration alters the CD4+FoxP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res. 2007, 67: 7487-7494. 10.1158/0008-5472.CAN-07-0565.PubMedCrossRef
27.
go back to reference Linn YC, Hui KM: Cytokine-induced NK-like T cells: from bench to bedside. J Biomed Biotechnol. 2010 Linn YC, Hui KM: Cytokine-induced NK-like T cells: from bench to bedside. J Biomed Biotechnol. 2010
28.
go back to reference Ayello J, van de Ven C, Cairo E, Hochberg J, Baxi L, Satwani P, Cairo MS: Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy. Exp Hematol. 2009, 37: 1216-1229. 10.1016/j.exphem.2009.07.009.PubMedCrossRef Ayello J, van de Ven C, Cairo E, Hochberg J, Baxi L, Satwani P, Cairo MS: Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy. Exp Hematol. 2009, 37: 1216-1229. 10.1016/j.exphem.2009.07.009.PubMedCrossRef
29.
go back to reference D'Andrea A, Rengaraju M, Valiante NM, Chehimi J, Kubin M, Aste M, Chan SH, Kobayashi M, Young D, Nickbarg E: Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med. 1992, 176: 1387-1398.PubMedCrossRef D'Andrea A, Rengaraju M, Valiante NM, Chehimi J, Kubin M, Aste M, Chan SH, Kobayashi M, Young D, Nickbarg E: Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med. 1992, 176: 1387-1398.PubMedCrossRef
30.
go back to reference Beyer M, Schultze JL: Regulatory T cells in cancer. Blood. 2006, 108: 804-811. 10.1182/blood-2006-02-002774.PubMedCrossRef Beyer M, Schultze JL: Regulatory T cells in cancer. Blood. 2006, 108: 804-811. 10.1182/blood-2006-02-002774.PubMedCrossRef
31.
go back to reference Dunne J, Lynch S, O'Farrelly C, Todryk S, Hegarty JE, Feighery C, Doherty DG: Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15. J Immunol. 2001, 167: 3129-3138.PubMedCrossRef Dunne J, Lynch S, O'Farrelly C, Todryk S, Hegarty JE, Feighery C, Doherty DG: Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15. J Immunol. 2001, 167: 3129-3138.PubMedCrossRef
32.
go back to reference Franceschetti M, Pievani A, Borleri G, Vago L, Fleischhauer K, Golay J, Introna M: Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp Hematol. 2009, 37: 616-628. 10.1016/j.exphem.2009.01.010. e612PubMedCrossRef Franceschetti M, Pievani A, Borleri G, Vago L, Fleischhauer K, Golay J, Introna M: Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp Hematol. 2009, 37: 616-628. 10.1016/j.exphem.2009.01.010. e612PubMedCrossRef
33.
go back to reference Lu PH, Negrin RS: A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol. 1994, 153: 1687-1696.PubMed Lu PH, Negrin RS: A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol. 1994, 153: 1687-1696.PubMed
34.
go back to reference Hoyle C, Bangs CD, Chang P, Kamel O, Mehta B, Negrin RS: Expansion of Philadelphia chromosome-negative CD3+CD56+ cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood. 1998, 92: 3318-3327.PubMed Hoyle C, Bangs CD, Chang P, Kamel O, Mehta B, Negrin RS: Expansion of Philadelphia chromosome-negative CD3+CD56+ cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood. 1998, 92: 3318-3327.PubMed
35.
go back to reference Dalle JH, Dardari R, Menezes J, Cordeiro P, Champagne MA, Duval M: Binding of thymoglobulin to natural killer cells leads to cell activation and interferon-γ production. Transplantation. 2009, 87: 473-481. 10.1097/TP.0b013e3181949c57.PubMedCrossRef Dalle JH, Dardari R, Menezes J, Cordeiro P, Champagne MA, Duval M: Binding of thymoglobulin to natural killer cells leads to cell activation and interferon-γ production. Transplantation. 2009, 87: 473-481. 10.1097/TP.0b013e3181949c57.PubMedCrossRef
36.
go back to reference Penack O, Fischer L, Gentilini C, Nogai A, Muessig A, Rieger K, Ganepola S, Thiel E, Uharek L: The type of ATG matters -- natural killer cells are influenced differentially by Thymoglobulin, Lymphoglobulin and ATG-Fresenius. Transpl Immunol. 2007, 18: 85-87. 10.1016/j.trim.2007.05.001.PubMedCrossRef Penack O, Fischer L, Gentilini C, Nogai A, Muessig A, Rieger K, Ganepola S, Thiel E, Uharek L: The type of ATG matters -- natural killer cells are influenced differentially by Thymoglobulin, Lymphoglobulin and ATG-Fresenius. Transpl Immunol. 2007, 18: 85-87. 10.1016/j.trim.2007.05.001.PubMedCrossRef
37.
go back to reference Makrigiannis AP, Anderson SK: Regulation of natural killer cell function. Cancer Biol Ther. 2003, 2: 610-616.PubMedCrossRef Makrigiannis AP, Anderson SK: Regulation of natural killer cell function. Cancer Biol Ther. 2003, 2: 610-616.PubMedCrossRef
38.
go back to reference Mingari MC, Schiavetti F, Ponte M, Vitale C, Maggi E, Romagnani S, Demarest J, Pantaleo G, Fauci AS, Moretta L: Human CD8+ T lymphocyte subsets that express HLA class I-specific inhibitory receptors represent oligoclonally or monoclonally expanded cell populations. Proc Natl Acad Sci USA. 1996, 93: 12433-12438. 10.1073/pnas.93.22.12433.PubMedPubMedCentralCrossRef Mingari MC, Schiavetti F, Ponte M, Vitale C, Maggi E, Romagnani S, Demarest J, Pantaleo G, Fauci AS, Moretta L: Human CD8+ T lymphocyte subsets that express HLA class I-specific inhibitory receptors represent oligoclonally or monoclonally expanded cell populations. Proc Natl Acad Sci USA. 1996, 93: 12433-12438. 10.1073/pnas.93.22.12433.PubMedPubMedCentralCrossRef
39.
go back to reference Vely F, Peyrat M, Couedel C, Morcet J, Halary F, Davodeau F, Romagne F, Scotet E, Saulquin X, Houssaint E: Regulation of inhibitory and activating killer-cell Ig-like receptor expression occurs in T cells after termination of TCR rearrangements. J Immunol. 2001, 166: 2487-2494.PubMedCrossRef Vely F, Peyrat M, Couedel C, Morcet J, Halary F, Davodeau F, Romagne F, Scotet E, Saulquin X, Houssaint E: Regulation of inhibitory and activating killer-cell Ig-like receptor expression occurs in T cells after termination of TCR rearrangements. J Immunol. 2001, 166: 2487-2494.PubMedCrossRef
40.
go back to reference Li G, Yu M, Weyand CM, Goronzy JJ: Epigenetic regulation of killer immunoglobulin-like receptor expression in T cells. Blood. 2009, 114: 3422-3430. 10.1182/blood-2009-01-200170.PubMedPubMedCentralCrossRef Li G, Yu M, Weyand CM, Goronzy JJ: Epigenetic regulation of killer immunoglobulin-like receptor expression in T cells. Blood. 2009, 114: 3422-3430. 10.1182/blood-2009-01-200170.PubMedPubMedCentralCrossRef
41.
go back to reference Arlettaz L, Degermann S, De Rham C, Roosnek E, Huard B: Expression of inhibitory KIR is confined to CD8+ effector T cells and limits their proliferative capacity. Eur J Immunol. 2004, 34: 3413-3422. 10.1002/eji.200324756.PubMedCrossRef Arlettaz L, Degermann S, De Rham C, Roosnek E, Huard B: Expression of inhibitory KIR is confined to CD8+ effector T cells and limits their proliferative capacity. Eur J Immunol. 2004, 34: 3413-3422. 10.1002/eji.200324756.PubMedCrossRef
42.
go back to reference Bonanno G, Mariotti A, Procoli A, Corallo M, Scambia G, Pierelli L, Rutella S: Interleukin-21 induces the differentiation of human umbilical cord blood CD34-lineage- cells into pseudomature lytic NK cells. BMC Immunology. 2009, 10: 46-10.1186/1471-2172-10-46.PubMedPubMedCentralCrossRef Bonanno G, Mariotti A, Procoli A, Corallo M, Scambia G, Pierelli L, Rutella S: Interleukin-21 induces the differentiation of human umbilical cord blood CD34-lineage- cells into pseudomature lytic NK cells. BMC Immunology. 2009, 10: 46-10.1186/1471-2172-10-46.PubMedPubMedCentralCrossRef
43.
go back to reference Eagle RA, Trowsdale J: Promiscuity and the single receptor: NKG2D. Nat Rev Immunol. 2007, 7: 737-744. 10.1038/nri2144.PubMedCrossRef Eagle RA, Trowsdale J: Promiscuity and the single receptor: NKG2D. Nat Rev Immunol. 2007, 7: 737-744. 10.1038/nri2144.PubMedCrossRef
44.
go back to reference Kaiser BK, Pizarro JC, Kerns J, Strong RK: Structural basis for NKG2A/CD94 recognition of HLA-E. Proc Natl Acad Sci USA. 2008, 105: 6696-6701. 10.1073/pnas.0802736105.PubMedPubMedCentralCrossRef Kaiser BK, Pizarro JC, Kerns J, Strong RK: Structural basis for NKG2A/CD94 recognition of HLA-E. Proc Natl Acad Sci USA. 2008, 105: 6696-6701. 10.1073/pnas.0802736105.PubMedPubMedCentralCrossRef
45.
go back to reference Borrego F, Masilamani M, Kabat J, Sanni TB, Coligan JE: The cell biology of the human natural killer cell CD94/NKG2A inhibitory receptor. Mol Immunol. 2005, 42: 485-488. 10.1016/j.molimm.2004.07.031.PubMedCrossRef Borrego F, Masilamani M, Kabat J, Sanni TB, Coligan JE: The cell biology of the human natural killer cell CD94/NKG2A inhibitory receptor. Mol Immunol. 2005, 42: 485-488. 10.1016/j.molimm.2004.07.031.PubMedCrossRef
46.
go back to reference Gunturi A, Berg RE, Forman J: The role of CD94/NKG2 in innate and adaptive immunity. Immunol Res. 2004, 30: 29-34. 10.1385/IR:30:1:029.PubMedCrossRef Gunturi A, Berg RE, Forman J: The role of CD94/NKG2 in innate and adaptive immunity. Immunol Res. 2004, 30: 29-34. 10.1385/IR:30:1:029.PubMedCrossRef
47.
go back to reference Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E, Augugliaro R, Moretta L, Moretta A: NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med. 1998, 187: 2065-2072. 10.1084/jem.187.12.2065.PubMedPubMedCentralCrossRef Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E, Augugliaro R, Moretta L, Moretta A: NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med. 1998, 187: 2065-2072. 10.1084/jem.187.12.2065.PubMedPubMedCentralCrossRef
48.
go back to reference Moretta L, Moretta A: Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J. 2004, 23: 255-259. 10.1038/sj.emboj.7600019.PubMedPubMedCentralCrossRef Moretta L, Moretta A: Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J. 2004, 23: 255-259. 10.1038/sj.emboj.7600019.PubMedPubMedCentralCrossRef
49.
go back to reference Trinchieri G, Pflanz S, Kastelein RA: The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity. 2003, 19: 641-644. 10.1016/S1074-7613(03)00296-6.PubMedCrossRef Trinchieri G, Pflanz S, Kastelein RA: The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity. 2003, 19: 641-644. 10.1016/S1074-7613(03)00296-6.PubMedCrossRef
Metadata
Title
Thymoglobulin, interferon-γ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures
Authors
Giuseppina Bonanno
Paola Iudicone
Andrea Mariotti
Annabella Procoli
Annino Pandolfi
Daniela Fioravanti
Maria Corallo
Alessandro Perillo
Giovanni Scambia
Luca Pierelli
Sergio Rutella
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2010
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-8-129

Other articles of this Issue 1/2010

Journal of Translational Medicine 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.